Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Breast Cancer Adjuvant treatment Condition: Administer during and following paclitaxel or docetaxel chemotherapy |
Dose: Intravenous infusion – 4 mg/kg Frequency: once, then 2 mg/kg once weekly Duration: first 12 weeks Note: Initial dose over 90 minutes, subsequent weekly doses over 30 minutes. |
|
Indication: Breast Cancer Adjuvant treatment Condition: Administer during and following docetaxel/carboplatin chemotherapy |
Dose: Intravenous infusion – 4 mg/kg Frequency: once, then 2 mg/kg once weekly Duration: first 18 weeks Note: Initial dose over 90 minutes, subsequent weekly doses over 30 minutes. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Safety and efficacy not established Note: Not recommended |
Administration
- Must be administered through IV infusion only
- Initial dose should be given over 90 minutes
Side Effect
- Pain (47%)
- Asthenia (42%)
- Fever (36%)
- Nausea (33%)
- Chills (32%)
- Cough (26%)
- Headache (26%)
- Diarrhea (25%)
- Vomiting (23%)
- Abdominal pain (22%)
- Back pain (22%)
- Dyspnea (22%)
- Infection (20%)
- Rash (18%)
- Anorexia (14%)
- Insomnia (14%)
- Flu-like syndrome (10%)
- Peripheral edema (10%)
- CHF (7%)
- Depression (6%)
- Tachycardia (5%)
- UTI (5%)
- Anemia (4%)
- Hypersensitivity (3%)
- Severe hypersensitivity (anaphylaxis) and infusion reactions
- pulmonary events eg acute respiratory distress syndrome
- cardiotoxicity
- Neutropenia (especially when given with chemotherapy)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Anthracyclines
|
Increased risk of severe cardiotoxicity
|
|
Paclitaxel
|
Increased risk of leukopenia and anaemia in combination chemotherapy
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Do not administer by rapid IV/bolus
|
Risk of severe reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store the vial in original carton at 2°C to 8°C. Protect from light. Keep out of the reach of children. Store reconstituted Trastuzumab in the refrigerator at 2°C to 8°C, discard unused Trastuzumab after 28 days. If Trastuzumab is reconstituted with SWFI without preservative, use immediately and discard any unused portion. Do not freeze. The solution of Trastuzumab for infusion diluted in 0.9% Sodium Chloride Injection, USP, should be stored at 2°C to 8°C for no more than 24 hours prior to use. Do not freeze.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.